Drug Database
Back to search

Netherlands· NL-28044d058604

Jalra 50 mg, tabletten

A vildagliptin product containing vildagliptine, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 16 of our 19 countries.

ATC A10BH02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedJalra 50 mg, tablettenATCA10BH02REGISTER NO.NL-28044d058604PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about vildagliptineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Vildagliptin is registered in 16 of 19 countries.

Countries holding a registration under ATC A10BH02 (vildagliptin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search vildagliptin products by name

Vildagliptin · ATC A10BH02

16 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of vildagliptin costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $0.32 in France to $1.98 in Switzerland — a ×6.2 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Vildagliptin · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.98
  • IT Italy$1.0
  • FR France$0.32
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
VILDAGLIPTINE
Manufacturer
Novartis Europharm Limited
Country
Netherlands (NL)
ATC code
A10BH02
ATC class
Vildagliptin
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/08/485

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vildagliptin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vildagliptin products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Melkart, Saxotin
  • Belgium · Vildagliptin Krka
  • Bulgaria · Глипвило, Далмевин
  • Cyprus · Aglimon, Dalmevin
  • Czechia · Alikval, Anvildis
  • Germany · Vildabetes, Vildagliptin Al
  • Denmark · Vildagliptin "a. E. Tiefenbacher", Vildagliptin "axunio"
  • Estonia · Dalmevin, Glypvilo
  • Spain · Vildagliptina, Vildagliptina Alter
  • Finland · Vildagliptin Krka, Vildagliptin Ratiopharm
  • France · Vildagliptine Accord, Vildagliptine Arrow
  • United Kingdom (Northern Ireland) · Vildagliptin, Vildagliptin Accord-Uk
  • Greece · Dalmevin, Varbos
  • Croatia · Agnis, Dalmevin
  • Hungary · Agartha, Alikval
  • Ireland · Vildagliptin Krka
  • Iceland · Galvus, Jalra
  • Italy · Vildagliptin Accord, Vildagliptin Aurobindo
  • Liechtenstein · Galvus, Jalra
  • Lithuania · Dalmevin, Glypvilo
  • Latvia · Dalmevin, Glypvilo
  • Malta · Alikval, Dalmevin
  • Norway · Galvus, Jalra
  • Poland · Anvildis, Diptivil
  • Portugal · Tutecvi, Vezagla
  • Romania · Agartha, Dalmevin
  • Sweden · Dalmevin, Kwikaton
  • Slovenia · Glypvilo
  • Slovakia · Anvildis, Dalmevin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dcea2566-8462-4f32-8d3a-db7adca4b86c
GET /v1/drugs/dcea2566-8462-4f32-8d3a-db7adca4b86c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/jalra-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Vildagliptin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp103256",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "LACTOSE 0-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT"
  ],
  "substances": [
    "VILDAGLIPTINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2008/11/19",
  "procedure_number": "EMEA/H/C/001048",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/08/485",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about vildagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console